How Many Seattle Genetics, Inc. (NASDAQ:SGEN)’s Analysts Are Bullish?

September 15, 2018 - By Pearl Odom

Seattle Genetics, Inc. (NASDAQ:SGEN) LogoInvestors sentiment decreased to 1.24 in Q2 2018. Its down 0.37, from 1.61 in 2018Q1. It fall, as 23 investors sold Seattle Genetics, Inc. shares while 68 reduced holdings. 41 funds opened positions while 72 raised stakes. 160.01 million shares or 0.31% more from 159.52 million shares in 2018Q1 were reported.
Mark Sheptoff Fincl Planning Ltd Liability Corporation has 200 shares. Ellington Mgmt Ltd has invested 0.02% in Seattle Genetics, Inc. (NASDAQ:SGEN). State Street invested in 2.88M shares or 0.02% of the stock. Goldman Sachs Group Inc Inc holds 2.92 million shares or 0.05% of its portfolio. Wellington Gp Llp holds 10.41 million shares or 0.15% of its portfolio. Cwm Ltd Llc, a Nebraska-based fund reported 200 shares. Reilly Fincl Advisors Ltd Liability Corporation has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). 115,610 were reported by Neuberger Berman Group. Sumitomo Mitsui Asset Mngmt invested in 6,327 shares. The South Africa-based Old Mutual Customised Solutions (Proprietary) Ltd has invested 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Financial Bank Of America De owns 270,536 shares. Capital Invsts reported 6.13 million shares. State Board Of Administration Of Florida Retirement System stated it has 148,059 shares or 0.03% of all its holdings. 150 were accumulated by Cornerstone Advsr Inc. Numerixs Invest Inc holds 0.04% or 2,400 shares.

Since March 15, 2018, it had 2 insider purchases, and 15 insider sales for $63.85 million activity. Shares for $306,058 were sold by LIU JEAN I. BAKER BROS. ADVISORS LP had bought 1.00M shares worth $51.26M. HIMES VAUGHN B had sold 5,000 shares worth $290,604. 9,000 shares were sold by Cline Darren S, worth $497,983 on Wednesday, May 9. Another trade for 5,427 shares valued at $402,856 was sold by SIMPSON TODD E.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Among 5 analysts covering Seattle Genetics (NASDAQ:SGEN), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seattle Genetics had 5 analyst reports since March 20, 2018 according to SRatingsIntel. The firm has “Overweight” rating by Morgan Stanley given on Wednesday, March 21. The company was upgraded on Monday, June 11 by SunTrust. The stock has “Buy” rating by H.C. Wainwright on Friday, April 27. The company was maintained on Friday, July 27 by JP Morgan. On Tuesday, March 20 the stock rating was maintained by RBC Capital Markets with “Buy”. Below is a list of Seattle Genetics, Inc. (NASDAQ:SGEN) latest ratings and price target changes.

27/07/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $66 New Target: $77 Maintain
11/06/2018 Broker: SunTrust Rating: Buy Upgrade
27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0000 Maintain
21/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $67 Maintain
20/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $73.0 Maintain

The stock increased 1.16% or $0.9 during the last trading session, reaching $78.16. About 481,912 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 44.99% since September 15, 2017 and is uptrending. It has outperformed by 29.37% the S&P500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $12.41 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

More recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on September 07, 2018. Also Seekingalpha.com published the news titled: “Your Cancer Highlight: Loxo Breaks Through Again, Now With Its Own Drug” on September 07, 2018. Seekingalpha.com‘s news article titled: “Seattle Genetics Is A Solid Buy In 2018” with publication date: August 27, 2018 was also an interesting one.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.